Integrated DNA Technologies (IDT), a Danaher company and global genomics leader, has announced a strategic collaboration with Ansa Biotechnologies, a specialist in DNA synthesis, to expand IDT’s synthetic biology offerings.

 

The partnership brings Ansa’s Clonal DNA and XL Clonal DNA products—spanning 100 base pairs to 50 kilobases—to IDT customers, enabling researchers to design and assemble longer, more complex DNA constructs for next-generation cell and gene therapy, vaccine development, and agrigenomics.

 

By combining IDT’s nearly 40-year legacy of quality and global reach with Ansa’s breakthrough enzymatic DNA synthesis platform, the collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability. Each sequence undergoes rigorous verification for GC content, homopolymers, and repetitive elements, reducing the risk of rework and troubleshooting.

 

“Customers face unprecedented complexity in their research, and they deserve solutions that make progress simpler and faster,” said IDT President Ajay Gannerkote. 

 

“IDT’s partnership with Ansa reflects the combination of proven reliability and trust with innovation in synthetic biology to deliver exactly that. This collaboration will help ensure researchers can come to IDT for their needs across every dimension of complexity, enabling breakthroughs that truly matter.”

 

Highlighting the practical impact, Manos Papadakis, Senior Research Scientist – Strain Development at DSM-Firmenich, said: “Our collaboration on the synthesis and delivery of complex constructs, powered by Ansa’s technology, has delivered clear value to our R&D site, enabling us to test ideas and pursue approaches that would otherwise not be feasible. The support and expertise provided by IDT has been critical to advancing our synthetic biology projects.”

 

Jason T Gammack, CEO of Ansa, added: “Ansa was founded to solve the hardest problems in DNA synthesis: length, complexity, and reliability. Through our collaboration with IDT, we are dismantling long-standing technical barriers and enabling more researchers worldwide to push the boundaries of science with greater confidence and without compromise.”

 

Ansa’s proprietary enzymatic platform allows researchers to design and assemble critical DNA constructs at scale without harsh chemicals, preserving DNA integrity while supporting longer, more complex sequences. Manufactured exclusively in the United States, the products integrate seamlessly into existing workflows, guided by rigorous biosecurity standards and full compliance with US OSTP nucleic acid synthesis regulations.